Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334406 | 0.92 | BRAF (0.59) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4327821 | 0.92 | BRAF (0.55) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4329327 | 0.89 | BRAF (0.55) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4328384 | 0.88 | BRAF (0.69) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4334619 | 0.86 | BRAF (0.61) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4331356 | 0.85 | BRAF (0.60) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4332407 | 0.85 | BRAF (0.60) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4339440 | 0.85 | BRAF (0.58) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4333326 | 0.84 | BRAF (0.64) | BRAFKDRLCKFYNPDGFRB | |
| SCHEMBL4321886 | 0.84 | BRAF (0.66) | BRAFKDRLCKFYNPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | COSTALES ABRAN (US) | 2013-08-29 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-1682126-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| US-7423150-B2 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2008-09-09 | — | — | US | disclosed |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | BRAF, RAF1, ARAF | BRAF 1/4885KDR 1373/4885LCK 279/4885 |
| US-20130224195-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | BRAF 1/4885KDR 1373/4885LCK 279/4885 |
| US-20050192287-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | BRAF 1/4885KDR 1373/4885LCK 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.